These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

513 related items for PubMed ID: 23664150

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Results of intravitreal ranibizumab with a prn regimen in the treatment of extrafoveal and juxtafoveal neovascular membranes in age-related macular degeneration.
    Giacomelli G, Giansanti F, Finocchio L, Biagini I, Bacherini D, Virgili G, Menchini U.
    Retina; 2014 May; 34(5):860-7. PubMed ID: 24756034
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration.
    Kang HM, Kwon HJ, Yi JH, Lee CS, Lee SC.
    Am J Ophthalmol; 2014 May; 157(5):1013-21. PubMed ID: 24487050
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Prognostic factors of eyes with naïve subfoveal myopic choroidal neovascularization after intravitreal bevacizumab.
    Yang HS, Kim JG, Kim JT, Joe SG.
    Am J Ophthalmol; 2013 Dec; 156(6):1201-1210.e2. PubMed ID: 24075429
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Systemic beta-blockers may reduce the need for repeated intravitreal injections in patients with wet age-related macular degeneration treated by bevacizumab.
    Montero JA, Ruiz-Moreno JM, Sanchis-Merino E, Perez-Martin S.
    Retina; 2013 Mar; 33(3):508-12. PubMed ID: 23099497
    [Abstract] [Full Text] [Related]

  • 13. Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration.
    Rothenbuehler SP, Waeber D, Brinkmann CK, Wolf S, Wolf-Schnurrbusch UE.
    Am J Ophthalmol; 2009 May; 147(5):831-7. PubMed ID: 19217019
    [Abstract] [Full Text] [Related]

  • 14. Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series.
    Iacono P, Parodi MB, Papayannis A, Kontadakis S, Sheth S, Bandello F.
    Retina; 2011 Oct; 31(9):1841-7. PubMed ID: 21775926
    [Abstract] [Full Text] [Related]

  • 15. Intravitreal bevacizumab for exudative age-related macular degeneration: effect on different subfoveal membranes.
    Tao Y, Jonas JB.
    Retina; 2010 Oct; 30(9):1426-31. PubMed ID: 20539255
    [Abstract] [Full Text] [Related]

  • 16. REFRACTORY INTRARETINAL OR SUBRETINAL FLUID IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL RANIZUBIMAB: Functional and Structural Outcome.
    Gianniou C, Dirani A, Jang L, Mantel I.
    Retina; 2015 Jun; 35(6):1195-201. PubMed ID: 25650710
    [Abstract] [Full Text] [Related]

  • 17. Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization.
    Rouvas A, Petrou P, Douvali M, Ntouraki A, Vergados I, Georgalas I, Markomichelakis N.
    Retina; 2011 May; 31(5):871-9. PubMed ID: 21358461
    [Abstract] [Full Text] [Related]

  • 18. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
    Arevalo JF, Fromow-Guerra J, Sanchez JG, Maia M, Berrocal MH, Wu L, Saravia MJ, Costa RA, Pan-American Collaborative Retina Study Group.
    Retina; 2008 May; 28(10):1387-94. PubMed ID: 18827735
    [Abstract] [Full Text] [Related]

  • 19. Three-year results of visual outcome with disease activity-guided ranibizumab algorithm for the treatment of exudative age-related macular degeneration.
    Lala C, Framme C, Wolf-Schnurrbusch UE, Wolf S.
    Acta Ophthalmol; 2013 Sep; 91(6):526-30. PubMed ID: 22697404
    [Abstract] [Full Text] [Related]

  • 20. Treat-and-extend bevacizumab for neovascular age-related macular degeneration: the importance of baseline characteristics.
    Rush RB, Simunovic MP, Vandiver L, Aragon AV, Ysasaga JE.
    Retina; 2014 May; 34(5):846-52. PubMed ID: 24240560
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.